NCT06311864View on ClinicalTrials.gov

Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia with Daridorexant in Canada

Enrolling by invitationOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Insomnia
Interventions
DRUG

Daridorexant 50 mg

As indicated by the physician

Trial Locations (1)

H2Y 2H4

PROxy Network, an initiative of PeriPharm inc., Montreal

Sponsors

Lead Sponsor

PeriPharm
All Listed Sponsors
collaborator

Idorsia Pharmaceuticals Ltd.

INDUSTRY

lead

PeriPharm

OTHER

NCT06311864 - Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia with Daridorexant in Canada | Biotech Hunter | Biotech Hunter